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stop as confirmed by PCR and sequencing in our mouse model ( Figure S2A ). Additionally, we 141 transfected Fbxo9 mutant plasmids into 293T cells. Mutants lacking the F-box or TPR domains 142 showed a slight decrease in molecular weight whereas the mutant lacking bases corresponding 143 to exon 4 showed a much greater decrease in molecular weight ( Figure S2B ). The band size 144 correlated with the predicted molecular weight of a protein arising from cKO cells. This evidence 145 indicates that deletion of exon 4 in our mouse model results in a truncated protein lacking the 146 TPR and F-box domains.
148
Fbxo9 deletion leads to alterations in HSPC populations 149 By analyzing different hematopoietic populations isolated from BM of a healthy WT mouse, we 150 found that Fbxo9 is most highly expressed in short-and long-term HSCs as well as some 151 myeloid lineages ( Figure 3A) . To study the role of Fbxo9 in normal hematopoiesis, we deleted 
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The cKit + progenitor population (cKit + ) decreased in total number due to a decrease in 159 megakaryocyte-erythroid progenitors ( Figure 3F ). To determine whether loss of Fbxo9 alters 160 differentiation of HSPCs, we carried out a colony forming cell assay and found that LSKs 161 derived from Fbxo9 +/and Fbxo9 -/gave rise to fewer colonies, showing decreased ability of 162 HSPCs to differentiate and proliferate in response to cytokine stimulation ( Figure 3G ). We Figure 2B ).
181
To monitor disease onset, we performed flow cytometry on peripheral blood (PB) beginning 3 182 weeks post-Poly(I:C) injection. Cell surface markers for mature myeloid cells Gr1 and CD11b
183
were analyzed along with cKit to identify immature AML blasts. Analysis revealed that 184 Cbfb +/56M Fbxo9 +/+ mice tend to have early (2-3 weeks) expression of cKit + cells that diminishes 185 at weeks 6 and 9. Although not significantly different, the kinetics of the cKit + tumor population 186 following Fbxo9 deletion conversely expands at weeks 6 and 9 ( Figure 4A ). In addition, we 187 found that most of the mice developed AML within the expected latency period, though the 
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In addition, we analyzed secondary organs for signs of infiltration. The spleens from all groups 204 had splenomegaly ( Figure S4B ). H&E staining of spleen infiltration demonstrated that ~60% of 205 Cbfb +/56M Fbxo9 -/mice had complete effacement of the spleen architecture compared to only 206 9 30% of Cbfb +/56M Fbxo9 +/+ mice ( Figure 4E -F). Likewise, in the liver Cbfb +/56M Fbxo9 -/mice had 207 ~50% infiltration in half the cohort indicating a more aggressive disease even though they had a 208 similar time of survival to Cbfb +/56M Fbxo9 +/+ mice ( Figure 4G ). These findings suggest that loss 209 of Fbxo9 leads to increased infiltration of spleen and liver. Figure 5C ). Upon sacrifice, analysis of the BM, spleen, and PB by flow cytometry showed no 226 difference in tumor burden between the three cohorts ( Figure S5B ). Secondary transplantation 227 confirms that tumors lacking Fbxo9 are aggressive and lead to rapid progression of AML.
229

Loss of Fbxo9 leads to up-regulation of proteins associated with tumorigenicity 230
To identify potential Fbxo9 substrates and protein alterations in AML, we performed quantitative 231 MS on splenic tumor cells. We labeled proteins isolated with tandem mass tags, combined Figure 6C , Table S1 ).
239
The majority of these differentially expressed proteins localized to the cytoplasm where FBXO9 240 is expressed ( Figure 6D 
271
The molecular pathogenesis of AML has yet to be fully defined, though many acquired 272 molecular and cytogenetic abnormalities have been identified that lead to leukemogenesis 41 .
273
The majority of these alterations are thought to occur in the HSPCs and disease progression is 274 often thought to progress through the dysregulation of normal cellular mechanisms 42 . As FBXO9 275 is an E3 ligase highly expressed in HSPCs (the tumor initiating population) it is imperative to 276 understand the resulting changes in HSPC function upon loss of its expression. We first report 277 that loss of Fbxo9 correlates with a decrease in the Lincells of the BM but an increase in the 278 LSKs within that compartment. Second, we show that the increase is due to an expansion of Aberrant FBXO9 expression has previously been linked to disease progression in MM by 285 tagging mTORC1 components for degradation 25 . In this context, its overexpression was shown 286 to promote disease progression and FBXO9 has previously been classified as an oncogene.
287
Contrary to its role in MM, our studies demonstrate that FBXO9 expression is consistently 288 decreased across AML subtypes and that reduction of its E3 ligase activity promotes the 
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Antibodies were prepared in 5% BSA as indicated in supplemental materials and methods.
15
Horse Radish Peroxidase conjugated secondary antibodies (Jackson Laboratory) were 363 prepared in 5% milk as indicated in supplemental materials and methods.
365
RNA extraction and quantitative RT-PCR
366
Total RNA was harvested from BM cells using the RNeasy Kit (QIAGEN, Hilden, Germany).
367
Following extraction, total RNA was used for cDNA synthesis using the High Capacity RNA-to- 
